Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00585143 | Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly | PHASE1 | COMPLETED | 37 | — | — | Jan 1, 2008 | Oct 1, 2008 | Sep 28, 2012 | 6 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ABT-335 | DRUG | 45 mg once daily for 10 consecutive days |
| Rosuvastatin | DRUG | 10 mg once daily for 10 days |
Inclusion Criteria Body Mass Index (BMI) 19 to 33, inclusive Either normal kidney function, or mild or moderate kidney impairment Exclusion Criteria Use of any medications, vitamins and/or herbal supplements within 2 weeks prior to study drug administration, except those required for management ...